These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29707476)

  • 1. Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies.
    Kwan P; Mintzer S; Laurenza A; Patten A; Cartwright K
    Epilepsy Behav Case Rep; 2018; 9():1-5. PubMed ID: 29707476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.
    Resnick T; Patten A; Ngo LY; Malhotra M
    Epilepsy Behav; 2022 Mar; 128():108528. PubMed ID: 35078116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.
    Rektor I; Krauss GL; Inoue Y; Kaneko S; Williams B; Patten A; Malhotra M; Laurenza A; Wechsler RT
    Epilepsia; 2020 Jul; 61(7):1491-1502. PubMed ID: 32645213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India.
    Mehndiratta MM; Gulhane M; Jabeen SA; Patten A; Dash A; Malhotra M
    Epilepsia Open; 2021 Mar; 6(1):90-101. PubMed ID: 33681652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
    Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
    CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term open-label perampanel: Generalized tonic-clonic seizures in idiopathic generalized epilepsy.
    French JA; Wechsler RT; Trinka E; Brandt C; O'Brien TJ; Patten A; Salah A; Malhotra M
    Epilepsia Open; 2022 Sep; 7(3):393-405. PubMed ID: 35445567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Malhotra M; Patten A; Kaneko S
    Epilepsia Open; 2024 Apr; 9(2):501-512. PubMed ID: 37867420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence.
    Yamamoto T; Gil-Nagel A; Wheless JW; Kim JH; Wechsler RT
    Epilepsy Behav; 2022 Nov; 136():108885. PubMed ID: 36150304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies.
    Piña-Garza JE; Villanueva V; Rosenfeld W; Yoshinaga H; Patten A; Malhotra M
    Epilepsy Behav; 2022 Oct; 135():108901. PubMed ID: 36122531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
    Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
    Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy.
    Brandt C; Wechsler RT; O'Brien TJ; Patten A; Malhotra M; Ngo LY; Steinhoff BJ
    Seizure; 2020 Aug; 80():115-123. PubMed ID: 32563171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
    Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A
    Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perampanel: as adjunctive therapy in patients with partial-onset seizures.
    Plosker GL
    CNS Drugs; 2012 Dec; 26(12):1085-96. PubMed ID: 23179642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multivariable prediction model of a major treatment response for focal-onset seizures: A post-hoc analysis of Phase III trials of perampanel.
    Krauss GL; Ben-Menachem E; Wechsler RT; Patten A; Williams B; Laurenza A; Malhotra M
    Epilepsy Res; 2021 Aug; 174():106649. PubMed ID: 34022524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures.
    Fogarasi A; Flamini R; Milh M; Phillips S; Yoshitomi S; Patten A; Takase T; Laurenza A; Ngo LY
    Epilepsia; 2020 Jan; 61(1):125-137. PubMed ID: 31912493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perampanel: A Review in Drug-Resistant Epilepsy.
    Frampton JE
    Drugs; 2015 Sep; 75(14):1657-68. PubMed ID: 26370209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open-label Study 342 (FREEDOM Study).
    Yamamoto T; Lim SC; Ninomiya H; Kubota Y; Shin WC; Kim DW; Shin DJ; Hoshida T; Iida K; Ochiai T; Matsunaga R; Higashiyama H; Hiramatsu H; Kim JH
    Epilepsia Open; 2020 Jun; 5(2):274-284. PubMed ID: 32524053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First add-on perampanel for focal-onset seizures: An open-label, prospective study.
    Kim JH; Kim DW; Lee SK; Seo DW; Lee JW; Park HJ; Lee SA
    Acta Neurol Scand; 2020 Feb; 141(2):132-140. PubMed ID: 31745975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.